Michael T. Hemann

Michael T. Hemann

Associate Professor of Biology

Michael T. Hemann uses mouse models to combat cancers resistant to chemotherapy.

617-324-1964

Phone

76-361

Office

Ryan Hayman

Assistant

617-253-0796

Assistant Phone

Education

PhD 2001, Johns Hopkins University

Research Summary

Many human cancers do not respond to chemotherapy, and often times those that initially respond eventually acquire drug resistance. Our lab uses high-throughput screening technology — combined with murine stem reconstitution and tumor transplantation systems — to investigate the genetic basis for this resistance. Our goal is to identify novel cancer drug targets, as well as strategies for tailoring existing cancer therapies to target the vulnerabilities associated with specific malignancies.

Key Publications

  1. Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution. Zhao, B, Sedlak, JC, Srinivas, R, Creixell, P, Pritchard, JR, Tidor, B, Lauffenburger, DA, Hemann, MT. 2016. Cell 165, 234-246.
    doi: 10.1016/j.cell.2016.01.045PMID:26924578
  2. DNA damage-mediated induction of a chemoresistant niche. Gilbert, LA, Hemann, MT. 2010. Cell 143, 355-66.
    doi: 10.1016/j.cell.2010.09.043PMID:21029859
  3. The combined status of ATM and p53 link tumor development with therapeutic response. Jiang, H, Reinhardt, HC, Bartkova, J, Tommiska, J, Blomqvist, C, Nevanlinna, H, Bartek, J, Yaffe, MB, Hemann, MT. 2009. Genes Dev. 23, 1895-909.
    doi: 10.1101/gad.1815309PMID:19608766
  4. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Hemann, MT, Bric, A, Teruya-Feldstein, J, Herbst, A, Nilsson, JA, Cordon-Cardo, C, Cleveland, JL, Tansey, WP, Lowe, SW. 2005. Nature 436, 807-11.
    doi: 10.1038/nature03845PMID:16094360
  5. An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo. Hemann, MT, Fridman, JS, Zilfou, JT, Hernando, E, Paddison, PJ, Cordon-Cardo, C, Hannon, GJ, Lowe, SW. 2003. Nat. Genet. 33, 396-400.
    doi: 10.1038/ng1091PMID:12567186

Recent Publications

  1. Drugs, Bugs, and Cancer: Fusobacterium nucleatum Promotes Chemoresistance in Colorectal Cancer. Ramos, A, Hemann, MT. 2017. Cell 170, 411-413.
    doi: 10.1016/j.cell.2017.07.018PMID:28753421
  2. PHF6 regulates phenotypic plasticity through chromatin organization within lineage-specific genes. Soto-Feliciano, YM, Bartlebaugh, JME, Liu, Y, Sánchez-Rivera, FJ, Bhutkar, A, Weintraub, AS, Buenrostro, JD, Cheng, CS, Regev, A, Jacks, TE et al.. 2017. Genes Dev. 31, 973-989.
    doi: 10.1101/gad.295857.117PMID:28607179
  3. A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress. Bruno, PM, Liu, Y, Park, GY, Murai, J, Koch, CE, Eisen, TJ, Pritchard, JR, Pommier, Y, Lippard, SJ, Hemann, MT et al.. 2017. Nat. Med. 23, 461-471.
    doi: 10.1038/nm.4291PMID:28263311
  4. A senescence secretory switch mediated by PI3K/AKT/mTOR activation controls chemoprotective endothelial secretory responses. Bent, EH, Gilbert, LA, Hemann, MT. 2016. Genes Dev. 30, 1811-21.
    doi: 10.1101/gad.284851.116PMID:27566778
  5. Rewiring the solid tumor epigenome for cancer therapy. Braun, CJ, Hemann, MT. 2016. Expert Rev Anticancer Ther 16, 977-87.
    doi: 10.1080/14737140.2016.1212663PMID:27410491
  6. Versatile in vivo regulation of tumor phenotypes by dCas9-mediated transcriptional perturbation. Braun, CJ, Bruno, PM, Horlbeck, MA, Gilbert, LA, Weissman, JS, Hemann, MT. 2016. Proc. Natl. Acad. Sci. U.S.A. 113, E3892-900.
    doi: 10.1073/pnas.1600582113PMID:27325776
  7. Exploiting Temporal Collateral Sensitivity in Tumor Clonal Evolution. Zhao, B, Sedlak, JC, Srinivas, R, Creixell, P, Pritchard, JR, Tidor, B, Lauffenburger, DA, Hemann, MT. 2016. Cell 165, 234-246.
    doi: 10.1016/j.cell.2016.01.045PMID:26924578
  8. A genome-scale in vivo loss-of-function screen identifies Phf6 as a lineage-specific regulator of leukemia cell growth. Meacham, CE, Lawton, LN, Soto-Feliciano, YM, Pritchard, JR, Joughin, BA, Ehrenberger, T, Fenouille, N, Zuber, J, Williams, RT, Young, RA et al.. 2015. Genes Dev. 29, 483-8.
    doi: 10.1101/gad.254151.114PMID:25737277
  9. From breaking bad to worse: exploiting homologous DNA repair deficiency in cancer. Hemann, MT. 2014. Cancer Discov 4, 516-8.
    doi: 10.1158/2159-8290.CD-14-0316PMID:24795010
  10. Sensitizing protective tumor microenvironments to antibody-mediated therapy. Pallasch, CP, Leskov, I, Braun, CJ, Vorholt, D, Drake, A, Soto-Feliciano, YM, Bent, EH, Schwamb, J, Iliopoulou, B, Kutsch, N et al.. 2014. Cell 156, 590-602.
    doi: 10.1016/j.cell.2013.12.041PMID:24485462
More Publications

Multimedia

Photo credit: Bryce Vickmark